Physician profile
William H Bailey
NPI 1184612863
$2,456.69
in general payments reported to CMS, 2019-2025
15 companies · $378 in 2025
The $378 reported for 2025 was more than what 91% of Emergency Medicine providers received nationally (typical 2025 total: $57.10).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $189 · 2020: $200 · 2021: $360 · 2022: $276 · 2023: $566 · 2024: $488 · 2025: $378.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,432.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,431.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $568.88 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $447.94 | 2019-2024 | Xarelto |
| E.R. Squibb & Sons, L.L.C. | $413.33 | 2019-2024 | Camzyos, Eliquis |
| Boehringer Ingelheim Pharmaceuticals, INC. | $242.84 | 2019-2025 | Jardiance |
| Scpharmaceuticals INC. | $234.70 | 2023-2025 | |
| Kestra Medical Technology Services, INC. | $138.15 | 2024-2025 | Assure Wcd |
| Novartis Pharmaceuticals Corporation | $96.98 | 2019-2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $59.66 | 2024 | Lifevest |
| Merck Sharp & Dohme LLC | $53.65 | 2025 | Winrevair |
| Amgen INC. | $52.26 | 2022-2025 | Repatha |
| Bayer Healthcare Pharmaceuticals INC. | $52.07 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $32.95 | 2022 | |
| Csl Behring | $26.45 | 2021 | |
| Novo Nordisk INC | $24.38 | 2025 | Wegovy |
| Smith+Nephew, INC. | $12.45 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Bailey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.